The state of bone metabolism in lung cancer patients by Dumansky, Y.V. et al.
136 Experimental Oncology 40, 136–139, 2018 (June)
THE STATE OF BONE METABOLISM IN LUNG CANCER PATIENTS
Y.V. Dumanskyy1, *, O.V. Syniachenko1, Ph.A. Stepko1, G.S. Taktashov1, O.Y. Chernyshova1, 
O.Y. Stoliarova2
1Donetsk National Medical University, Lyman 84400, Ukraine
2National Cancer Institute, Kyiv 03022, Ukraine
In recent years, we have discussed the correlation of malignant tumor process with the development of osteoporosis, which can 
be exacerbated by ongoing chemotherapy and radiation therapy. The aim of the work was to assess the status of bone metabolism 
in 32 untreated patients with lung cancer without metastasis. Materials and Methods: Patients underwent dual-energy X-ray os-
teodensitometry of proximal part of femoral bone. Osteopontin (OP), osteocalcin (OC) and alkaline phosphatase (AP) parameters 
were studied in blood, as well as osteo-associated chemical elements. Results: Lung cancer proceeds with severe disorders of bone 
metabolism, which is accompanied by an increase in blood levels of OP, OС, AP, phosphorus, lithium, lead, strontium and cobalt 
against a decrease of calcium, magnesium and manganese, which were observed in 75; 78; 31; 100; 66; 47; 44; 3; 100; 100, and 
6% of patients, respectively; such disorder was associated with a morphological variant of the tumor (cobalt) and stage of disease 
(calcium, magnesium, manganese, strontium), development of osteodeficit (OP, OC, AR, strontium, zinc). Osteodeficit in the 
form of osteopenia and osteoporosis is observed more common in women, in every second patient, and osteodensimetric T-score 
depends on the age of patients, directly correlates with the values of the OP and OC, and inversely — with a zincemia rate. Con-
clusions: The disorders of bone metabolism in patients with lung cancer indicate the need for the development of antiosteoporosis 
treatment for cancer patients.
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Lung cancer (LC) occupies the first place 
in the structure of oncological morbidity and it is one 
of the main causes of the death [1–3]. The incidence 
of LC is 62 per 100,000 population among men and 
30 per 100,000 among women, besides these pa-
rameters rise every year [4]. Every fourth case among 
all newly registered cancer patients and every third 
cancer-related death are related to LC [5].
The osteodeficiency is involved into the patho-
logical process in half of the number of the patients 
suffering from malignant tumors [6]. Osteoporosis 
in cancer patients is often formed as a result of arising 
defects of sexual and calcium regulating hormones 
in the body [7]. In LC the changes of bone mineral 
density take place and the prevalence of osteoporotic 
vertebral fractures achieves 30–40% of such patients 
according to clinical and sectional studies [8].
LC may be accompanied by the imbalance of osteo-
associated trace elements [9] and calcium metabolic 
disturbances with hyperproduction of osteocalcin (OC) 
and osteopontin (OP) relating to the main biochemical 
bone metabolism markers (BMM) [10]. It was observed 
that the increased synthesis of OC and OP which 
were involved in the processes of the reconstruction 
of bone tissue [11] and determined the development 
of osteoporosis [12] referred to the factors of adverse 
LC course [13, 14]. According to Kang et al. [15] and 
Li et al. [16], the presence of OP in the blood is directly 
associated with the presence of metastases in patients 
with LC. However, Zou et al. [17] suggested that the role 
of BMM in the development of non-small cell LC and 
osteoporosis remains controversial.
The aim of the study was to assess the level 
of changes of BMM and osteo-associated chemical 
elements in the blood of the patients with LC, their 
possible association with morphological variants 
of the disease, the stage of the pathological process 
and the presence of osteodeficiency (osteopenia, 
osteoporosis).
MATERIAL AND METHODS
The study included 32 patients with LC without 
distant metastases at the age of 35 to 76 years 
(on average 55.6 ± 2.1 years) who had not received 
chemo- or radiotherapy previously. The patients have 
been treated at Donetsk Regional Anticancer Center 
and National Cancer Institute (Kyiv), the study was 
approved by Donetsk National Medical University 
Bioethics Commission.
23 men (71.9%) and 9 (28.1%) women were among 
these patients. The duration of the manifestation 
of LC constituted 19.7 ± 1.5 months in average. The 
ratio of mediastinal, lower lobe, left-upper lower lobe, 
right-middle upper lobe and upper lobe localization 
was 1:1:2:2:2. 78.1% of the patients had the central 
form of LC and 21.9% — peripheral, ¼ — small cell 
LC and ¾ — non-small cell LC (adenocarcinoma, 
squamous and large cell carcinoma). The ratio of IA, IB, 
IIA, IIIB, IIB and IIIA stages of LC came to 1:2:3:3:4:4.
The methods of radiography, computed and 
magnetic resonance tomography (Multix-Compact-
Siemens, Germany; Somazom-Emotion-6-Siemens, 
Germany; Gygoscan-Intera-Philips, Netherlands) 
have been used for the diagnosis of the disease. Dual-
energy X-ray osteodensitometry of the proximal femur 
(QDR-4500-Delphi-Hologic, USA) has been performed. 
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In the context of the objectives of the study it indicates 
BMM — the maintenance of OC and OP in the blood 
serum. The activity of alkaline phosphatase (AP) was 
determined using the automated biochemical analyzer 
Olympus-AU640 (Japan), OC and OP values — by im-
munoassay analysis (reader PR2100-Sanofi Diagnostic 
Pasteur, France, set R&D-Systems, USA), the levels 
of osteo-associated chemical macroelements (cal-
cium — Ca, magnesium — Mg, phosphorus — P) — 
by atomic emission spectrometry with inductively bound 
argon plasma (apparatus IRIS-Intepid-II-XDL, United 
Kingdom) and microelements (iron — Fe, cobalt — Co, 
lithium — Li, manganese — Mn, copper — Cu, lead — 
Pb, strontium — Sr, zinc — Zn) — by atomic absorption 
spectrometry with electrographite atomizer (apparatus 
SolAAr-Mk2-MOZe, United Kingdom).
As a control group, 40 healthy individuals (22 men 
and 18 women, aged 41.7 ± 5.6 years) have been sur-
veyed and corresponding parameters were assessed.
Statistical processing of the data has been carried 
out using computer variation, nonparametric, correla-
tion, regression, one-way (ANOVA) and multivariate 
(ANOVA/MANOVA) analysis of variance (program 
Microsoft Excel and Statistica-Stat Soft, USA). Mean 
values (M), standard deviations (SD) and their stan-
dard errors (m), Pearson correlation coefficient (r), 
multiple regression (R), Brown and Forsythe’s test 
of variance (BF) and Wilcoxon — Rao (WR), Students’ 
t-test (t), MacNemar — Fisher (χ2), accuracy of statisti-
cal parameters (p) were calculated. The critical level 
of significance was taken as < 0.05.
RESULTS AND DISCUSSION
We have analyzed the indexes of bone metabo-
lism and have revealed that they differ significantly 
between the control group (healthy individuals) and 
patients with LC. As we have found (Table), in pa-
tients with LC parameters P increase by 14.3 times, 
OC — by 2.6 times, OP — by 81%, Li — by 74%, 
Pb — by 63%, Sr — by 54%, AP — by 35%, Co — 
by 24% with the decrease of Mg concentrations 
by 91%, Ca — by 46%, and Mn — by 31%. Thus, 
against the background of increasing the content 
of bone metabolism organic markers (AP, OC, OP) 
there is a deficit of essential (vital) microelements 
(Ca, Mg) in the hyperproduction of toxic microele-
ments (Co, Li, Pb, Sr). The changes (< M ± 2SD > 
healthy people) Ca, Mg, P, OC, OP, Li, Pb, Sr, AP, 
Mn, Co are found respectively in 100; 100; 100; 78; 
75; 66; 47; 44; 31; 6 and 3% of the patients with LC.
According to the results of multivariate analysis 
of variance of Wilcoxon — Rao, the integral state 
of BΜM and chemical elements are affected by the 
stage of LC (WR = 2.61, p = 0.047), but they are not 
influenced by patients’ gender and age, the duration 
and morphological form of the disease. As evidenced 
by one-way ANOVA of Brown — Forsythe, the duration 
of the disease affects phosphatemia level (BF = 7.97, 
p = 0.004), and the parameters of Ca (BF = 3.23, p = 
0.045) and Mg (BF = 4.04, p = 0.039) in the blood 
depend on the stage of LC. According to the patients’ 
age the values of OP (r = 0.397, p = 0.024) increase, 
but the concentration of Zn (r = −0.359, p = 0.048) 
decreases. There is a direct regression linkage 
of Sr level (R = 2.42, p = 0.027) and there is a reverse 
one of Mn level (R = −2.59, p = 0.019) with the stage 
of LC in the serum.
In blood of non-small cell LC patients, Co level 
was higher than in blood of patients with small cell 
LC by 11% (t = 3.33, p = 0.002) (Fig. 1). It should 
be noted that Co is included in cyanocobalamin and 
some enzymes (acylase, glycylglycine dipeptidase, 
cholinesterase), and the highest quantity of this ion 
is present in the liver and thyroid gland. Since all the 
salts of Co are chemical carcinogens, so this trace 
element is among the quite significant risk factors 
of LC. The increase of Co level in the bones is ac-
companied by the rise of the concentration of amino 
acids, monocyte chemotactic protein 1 and matrix 
metalloproteinases activity in the blood.
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Fig. 1. The changes of the parameters of BMM and chemical ele-
ments in patients: а) with small cell and non-small cell LC which 
are taken as 100%; b) with osteodeficiency and without it which 
are taken as 100%
Osteodeficiency (osteopenia, osteoporosis) has 
been diagnosed in 46.9% of the LC patients, and den-
sitometric T-test has been −1.17 ± 0.110 a.u. We have 
established gender dimorphism of osteodeficiency 
with its more frequent development in women suffer-
ing from LC (χ2 = 4.80, p = 0.028), while the frequency 
of osteopenia/osteoporosis was independent of the 
morphological variant of the disease (Fig. 2, 3). Ac-
cording to the data of ANOVA, the parameters 
of T-test are affected by the age of the patients with 
LC (BF = 6.28, p < 0.001), and as correlation analysis 
Table. Indices of bone metabolism in blood of healthy people and patients 
with LC (M ± SE)
Indices
Groups of surveyed Differences between groups
Control group  
(n = 40)
Patients with 
LC (n = 32) t p
OC, ng/ml
OP, ng/ml
AP, U/l
Ca, mg/l
Co, mg/l
Cu, mg/l
Fe, mg/l
Li, mg/l
Mg, mg/l
Mn, mg/l
P, mg/l
Pb, mg/l
Sr, mg/l
Zn, mg/l
5.3 ± 0.4
22.0 ± 0.9
90.0 ± 5.3
100.0 ± 0.6
6.6 ± 0.4
1.0 ± 0.03
439.9 ± 3.5
2.3 ± 0.04
412.2 ± 5.8
18.4 ± 2.2
27.8 ± 0.4
39.5 ± 2.6
32.4 ± 1.5
6.1 ± 0.1
13.8 ± 0.7
39.8 ± 1.3
121.1 ± 7.0
53.8 ± 1.3
8.2 ± 0.1
1.0 ± 0.02
398.6 ± 23.8
4.0 ± 0.3
35.9 ± 0.3
12.6 ±0.6
398.4 ± 2.7
64.2 ± 4.7
49.9 ± 3.2
6.3 ± 0.2
12.04
10.86
3.62
35.57
3.45
0.84
1.92
6.11
58.01
2.32
153.71
4.85
5.22
1.07
< 0.001
< 0.001
0.001
< 0.001
0.001
0.402
0.060
< 0.001
< 0.001
0.023
< 0.001
< 0.001
< 0.001
0.289
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demonstrated, there is a direct linkage of the parame-
ters of T-test with the levels of OC (r = 0.740, p < 0.001) 
and OP (r = 0.812, p < 0.001), and reverse one — with 
the indicators of zincemia (r = −0.572, p = 0.001).
-369,5428-150,7251*x+
77,6489*y+6,645*x*x-0,091*x*y-
1,105*y*y
without osteodeficiency
-2932,1204+67,8084*x+
110,9838*y+1,0839*x*x-2,2327*x*y-
0,8318*y*y
with osteodeficiency
a b
Fig. 3. Three-dimensional histograms of integral BMM param-
eters (OC + OP + AP) in patients with LC
Osteodeficiency in LC is accompanied by the in-
crease of the OC content in the blood serum by 30% 
(t  = 2.74, p = 0.010), OP — by 27% (t = 4.93, p < 0.001), 
AP — by 25% (t = 2.08, p = 0.047) and Sr — by 41% 
(t = 2.96; p = 0.006) with the decrease of Zn level 
(t = 2.44, p = 0.021) by 12%. We emphasize that Zn re-
fers to oncoprotective trace elements [18, 19].
Wulaningsih et al. [20] showed that a high level 
of P in the blood was a risk factor for the development 
of LC. The mechanisms which cause the lesion of bone 
tissue in the patients with LC are complex and they are 
the result of complex interactions of the tumor and the 
bone system. There are osteoblasts on the surface 
of the bone that produce matrix vesicles containing 
Ca and P, and the main function of these cells is protein 
synthesis, the formation of the collagen network, the 
production of OC, OP and other substances. Com-
pound components of the intercellular matrix bind 
adhesion proteins that interact with the cell receptors 
(integrins), fix the cells in the intercellular space.
Co, Cu, Fe, Mn, and Zn have unfilled d-electronic 
layers that determine their ability to participate in vari-
ous oxidizing and reduction processes in the bone. 
The imbalance of the levels of these trace elements 
in LC leads to metabolic and structural changes in bone 
tissue. Low Mg level in LC can increase the absorp-
tion of Ca and a high level of P activates this process. 
It should be noted that an excess of Mg usually results 
in the stimulation of osteoclasts and the abnormali-
ties of the structural and functional state of the bone 
and the development of hypercalciumemia observed 
in LC metastases into the bone; it is of differential 
and diagnostic value in osteopenia/osteoporosis. 
A reduced level of Mn in LC disturbs the biosynthesis 
of acid mucopolysaccharides, decreases the level 
of hexuronic acids, glucosamine and galactosamine 
in bone tissue, thereby stimulating the development 
of osteoporosis.
A considerable part of Pb entering the body accu-
mulates in bone tissue and in the case of the excess 
of its concentration in patients with LC bone density 
dramatically weakens. Pb in these patients is able 
to replace Ca in bone tissue and release during bone 
demineralization. In the patients with LC, low Ca level 
enhances the absorption of Pb, and the antagonist 
in this process is Zn depressing the level of bone Pb. 
Oncogenic Sr has tropic properties in regard to bone 
tissue, and participates in the processes of ossification 
along with Ca on the surface of the bone.
CONCLUSIONS
LC progresses with marked disorders of bone 
metabolism which are accompanied by the increase 
of P, OC, OP, Li, Pb, Sr, AP and Co levels in the blood, 
on the background of the reduction of Ca, Mg and 
Mn that are respectively observed in 100; 78; 75; 66; 
47; 44; 31; 3; 100; 100 and 6% of the patients. Modify-
ing bone metabolism is associated with morphological 
variant of the tumor (Co) and LC stage (Ca, Mg, Mn, 
Sr) as well as with the development of osteodeficiency 
(OC, OP, AP, Sr, Zn) which is seen in every second pa-
tient with LC in the form of osteopenia or osteoporosis, 
more common in women. Osteodensitometry T-score 
depends on the patients’ age, it is directly correlated 
with the values of OC and OP, and inversely — with 
concentration of Zn. The disorders of bone metabolism 
in LC indicate the need for the development of antios-
teoporosis treatment for cancer patients.
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Fig. 2. Correlation and regression linkages of densitometric reverse T-test with the parameters of BMM
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